Advertisement
Case study| Volume 50, P165-171, April 2018

Download started.

Ok

Changes in hormones of the hypothalamic-pituitary-gonadal axis in migraine patients

Published:January 22, 2018DOI:https://doi.org/10.1016/j.jocn.2017.11.011

      Highlights

      • The hormone levels in the HPG axis were abnormal in migraineurs.
      • The change of sex hormones had a significant correlation with the level of disability caused by the migraine.
      • The relationship between hormone levels and migraine related clinical characteristic was more apparent in female migraineur.

      Abstract

      The incidence of migraine is higher in women than in men. Abnormality of the hypothalamus-pituitary-gonadal (HPG) axis is believed to be implicated in the pathogenesis of migraine. The aim of this study was to detect serum hormone levels in the HPG axis of migraineurs and analyze the relationship between the hormone levels and migraine-related clinical characteristics. One hundred and nineteen migraineurs were enrolled. Serum FSH, LH, estradiol, progesterone, testosterone, prolactin and GnRH was detected. Pain intensity and migraine-related disability were evaluated using the visual analogue scale (VAS) and the Migraine Disability Assessment questionnaire (MIDAS). The relationships between sex hormone levels and the VAS score and the MIDAS score were also examined. Progesterone levels in male migraineurs were lower than those in healthy controls (P < .01). In female patients, in the follicular phase, testosterone levels were lower than in healthy controls (P < .01). In the luteal phase, estrogen and testosterone levels (P < .05) were lower than in healthy controls. Progesterone and testosterone levels (P < .01) were lower than in healthy controls in the postmenopausal phase. In male patients, estrogen levels were negatively associated with the MIDAS score (r = −0.602). In female patients, in the follicular phase, estrogen levels were positively correlated with headache duration and VAS score (r = 0.374, r = 0.331, respectively) and negatively related with MIDAS score (r = −0.334). In the luteal phase, estrogen and progesterone levels were negatively correlated with the MIDAS score (r = −0.772, r = −0.464, respectively). The levels of HPG axis hormones were abnormal in migraineurs and were associated with migraine-related clinical characteristics.

      Abbreviations:

      CGRP (calcitonin gene related peptide), E2 (Estrogen), FP (follicular phase), GABA (gamma-aminobutyric acid), HPG (hypothalamus-pituitary-gonadal), LH (luteinizing hormone), NO (nitric oxide), PRG (Progesterone), To (Testosterone), VAS (visual analogue scale), CSD (cortical spreading depression), fMRI (functional magnetic resonance imaging), FSH (follicle stimulating hormone), GnRH (gonadotropin-releasing hormone), LP (luteal phase), MIDAS (Migraine Disability Assessment questionnaire), PMP (postmenopausal phase), PRL (prolactin), TTH (tension-type headache)

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Clinical Neuroscience
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Yu S.
        • Liu R.
        • Zhao G.
        • et al.
        The prevalence and burden of primary headaches in China: a population-based door-to-door survey.
        Headache. 2012; 52: 582-591
        • Maleki N.
        • Linnman C.
        • Brawn J.
        • Burstein R.
        • Becerra L.
        • Borsook D.
        Her versus his migraine: multiple sex differences in brain function and structure.
        Brain J Neurol. 2012; 135: 2546-2559
        • Finocchi C.
        • Ferrari M.
        Female reproductive steroids and neuronal excitability.
        Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2011; 32: S31-35
        • MacGregor E.A.
        • Victor T.W.
        • Hu X.
        • et al.
        Characteristics of menstrual vs nonmenstrual migraine: a post hoc, within-woman analysis of the usual-care phase of a nonrandomized menstrual migraine clinical trial.
        Headache. 2010; 50: 528-538
        • Pinkerman B.
        • Holroyd K.
        Menstrual and nonmenstrual migraines differ in women with menstrually-related migraine.
        Cephalalgia Int J Headache. 2010; 30: 1187-1194
        • Aegidius K.
        • Zwart J.A.
        • Hagen K.
        • Stovner L.
        The effect of pregnancy and parity on headache prevalence: the Head-HUNT study.
        Headache. 2009; 49: 851-859
        • Frederick I.O.
        • Qiu C.
        • Enquobahrie D.A.
        • et al.
        Lifetime prevalence and correlates of migraine among women in a pacific northwest pregnancy cohort study.
        Headache. 2014; 54: 675-685
        • Glaser R.
        • Dimitrakakis C.
        • Trimble N.
        • Martin V.
        Testosterone pellet implants and migraine headaches: a pilot study.
        Maturitas. 2012; 71: 385-388
        • Cavestro C.
        • Rosatello A.
        • Marino M.P.
        • Micca G.
        • Asteggiano G.
        High prolactin levels as a worsening factor for migraine.
        J Headache Pain. 2006; 7: 83-89
      1. The International Classification of Headache Disorders. 2nd ed. Cephalalgia: An international journal of headache. 2004;24 Suppl 1:9–160.

        • Bosco D.
        • Belfiore A.
        • Fava A.
        • et al.
        Relationship between high prolactin levels and migraine attacks in patients with microprolactinoma.
        J Headache Pain. 2008; 9: 103-107
        • Patil M.J.
        • Henry M.A.
        • Akopian A.N.
        Prolactin receptor in regulation of neuronal excitability and channels.
        Channels (Austin, Tex). 2014; 8: 193-202
        • Eikermann-Haerter K.
        • Baum M.J.
        • Ferrari M.D.
        • van den Maagdenberg A.M.
        • Moskowitz M.A.
        • Ayata C.
        Androgenic suppression of spreading depression in familial hemiplegic migraine type 1 mutant mice.
        Ann Neurol. 2009; 66: 564-568
        • Perusquia M.
        • Stallone J.N.
        Do androgens play a beneficial role in the regulation of vascular tone? Nongenomic vascular effects of testosterone metabolites.
        Am J Physiol Heart Circ Physiol. 2010; 298: H1301-1307
        • Glaser R.
        • York A.E.
        • Dimitrakakis C.
        Beneficial effects of testosterone therapy in women measured by the validated Menopause Rating Scale (MRS).
        Maturitas. 2011; 68: 355-361
        • Merki-Feld G.S.
        • Imthurn B.
        • Langner R.
        • Seifert B.
        • Gantenbein A.R.
        Positive effects of the progestin desogestrel 75 mug on migraine frequency and use of acute medication are sustained over a treatment period of 180 days.
        J Headache Pain. 2015; 16: 522
        • Maximo M.M.
        • Silva P.S.
        • Vieira C.S.
        • et al.
        Low-dose progestin-releasing contraceptives are associated with a higher pain threshold in healthy women.
        Fertil Steril. 2015; 104: 1182-1189
        • Gupta S.
        • McCarson K.E.
        • Welch K.M.
        • Berman N.E.
        Mechanisms of pain modulation by sex hormones in migraine.
        Headache. 2011; 51: 905-922
        • Ibrahimi K.
        • van Oosterhout W.P.
        • van Dorp W.
        • et al.
        Reduced trigeminovascular cyclicity in patients with menstrually related migraine.
        Neurology. 2015; 84: 125-131
        • Pavlovic J.M.
        • Allshouse A.A.
        • Santoro N.F.
        • et al.
        Sex hormones in women with and without migraine: Evidence of migraine-specific hormone profiles.
        Neurology. 2016; 87: 49-56
        • De Icco R.
        • Cucinella L.
        • De Paoli I.
        • et al.
        Modulation of nociceptive threshold by combined hormonal contraceptives in women with oestrogen-withdrawal migraine attacks: a pilot study.
        J Headache Pain. 2016; 17: 70
        • Harte-Hargrove L.C.
        • Maclusky N.J.
        • Scharfman H.E.
        Brain-derived neurotrophic factor-estrogen interactions in the hippocampal mossy fiber pathway: implications for normal brain function and disease.
        Neuroscience. 2013; 239: 46-66
        • Cui J.
        • Shen Y.
        • Li R.
        Estrogen synthesis and signaling pathways during aging: from periphery to brain.
        Trends Molecul Med. 2013; 19: 197-209
        • Asl S.Z.
        • Khaksari M.
        • Khachki A.S.
        • Shahrokhi N.
        • Nourizade S.
        Contribution of estrogen receptors alpha and beta in the brain response to traumatic brain injury.
        J Neurosurg. 2013; 119: 353-361
        • Murray S.C.
        • Muse K.N.
        Effective treatment of severe menstrual migraine headaches with gonadotropin-releasing hormone agonist and “add-back” therapy.
        Fertil Steril. 1997; 67: 390-393
        • Smith J.T.
        Sex steroid regulation of kisspeptin circuits.
        Adv Exp Med Biol. 2013; 784: 275-295
        • Scharfman H.E.
        • MacLusky N.J.
        Estrogen-growth factor interactions and their contributions to neurological disorders.
        Headache. 2008; 48: S77-89
      2. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (London, England). 2015;386:743–800.

        • Macgregor E.A.
        • Rosenberg J.D.
        • Kurth T.
        Sex-related differences in epidemiological and clinic-based headache studies.
        Headache. 2011; 51: 843-859
        • MacGregor E.A.
        • Brandes J.
        • Eikermann A.
        • Giammarco R.
        Impact of migraine on patients and their families: the Migraine And Zolmitriptan Evaluation (MAZE) survey–Phase III.
        Curr Med Res Opin. 2004; 20: 1143-1150